{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:13Z","timestamp":1784612533325,"version":"3.55.0"},"reference-count":111,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI21\/0059"],"award-info":[{"award-number":["PI21\/0059"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"name":"RICORS","award":["RD21\/00050021"],"award-info":[{"award-number":["RD21\/00050021"]}]},{"name":"Bellvitge Univeristy Hospital","award":["VAR22002"],"award-info":[{"award-number":["VAR22002"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Different polymorphisms in genes encoding metabolizing enzymes and drug transporters have been associated with tacrolimus pharmacokinetics. In particular, studies on CYP3A4 and CYP3A5, and their combined cluster have demonstrated their significance in adjusting tacrolimus dosing to minimize under- and overexposure thereby increasing the proportion of patients who achieve tacrolimus therapeutic target. Many factors influence the pharmacokinetics of tacrolimus, contributing to inter-patient variability affecting individual dosing requirements. On the other hand, the growing use of population pharmacokinetic models in solid organ transplantation, including different tacrolimus formulations, has facilitated the integration of pharmacogenetic data and other variables into algorithms to easier implement the personalized dose adjustment in transplant centers. The future of personalized medicine in transplantation lies in implementing these models in clinical practice, with pharmacogenetics as a key factor to account for the high inter-patient variability in tacrolimus exposure. To date, three clinical trials have validated the clinical application of these approaches. The aim of this review is to provide an overview of the current studies regarding the different population pharmacokinetic including pharmacogenetics and those translated to the clinical practice for individualizing tacrolimus dose adjustment in kidney transplantation.<\/jats:p>","DOI":"10.1097\/ftd.0000000000001289","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:01:35Z","timestamp":1736348495000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Customizing Tacrolimus Dosing in Kidney Transplantation: Focus on Pharmacogenetics"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3387-5757","authenticated-orcid":false,"given":"Nuria","family":"Lloberas","sequence":"first","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL); and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Vidal-Alabr\u00f3","sequence":"additional","affiliation":[{"name":"Nephrology Department, Hospital Universitari de Bellvitge-Institut d'Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL); and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Colom","sequence":"additional","affiliation":[{"name":"Biopharmaceutics and Pharmacokinetics Unit, Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry, School of Pharmacy and Food Sciences, University of Barcelona, Barcelona, Spain."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,10]]},"reference":[{"key":"R1-20250108","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1016\/j.kint.2018.05.018","article-title":"Analyses of the short- and long-term graft survival after kidney transplantation in Europe between 1986 and 2015","volume":"94","author":"Coemans","year":"2018","journal-title":"Kidney Int"},{"key":"R2-20250108","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","article-title":"Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation","volume":"43","author":"Staatz","year":"2004","journal-title":"Clin Pharmacokinet"},{"key":"R3-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","article-title":"Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report","volume":"41","author":"Brunet","year":"2019","journal-title":"Ther Drug Monit"},{"key":"R4-20250108","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1056\/NEJMoa067411","article-title":"Reduced exposure to calcineurin inhibitors in renal transplantation","volume":"357","author":"Ekberg","year":"2007","journal-title":"N Engl J Med"},{"key":"R5-20250108","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1097\/TP.0000000000002052","article-title":"High intrapatient variability of tacrolimus exposure in the early period after liver transplantation is associated with poorer outcomes","volume":"102","author":"Rayar","year":"2018","journal-title":"Transplantation"},{"key":"R6-20250108","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1111\/ajt.14109","article-title":"Reduction of extended-release tacrolimus dose in low-immunological-risk kidney transplant recipients increases risk of rejection and appearance of donor-specific antibodies: a randomized Study","volume":"17","author":"Gatault","year":"2017","journal-title":"Am J Transpl"},{"key":"R7-20250108","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.clpt.2003.12.009","article-title":"Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients","volume":"75","author":"Kuypers","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"R8-20250108","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/S0041-1345(98)01633-9","article-title":"Low systemic exposure to tacrolimus correlates with acute rejection","volume":"31","author":"Undre","year":"1999","journal-title":"Transpl Proc"},{"key":"R9-20250108","first-page":"721","article-title":"Optimization of initial tacrolimus dose using pharmacogenetic testing","volume":"87","author":"Thervet","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R10-20250108","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1111\/ajt.13691","article-title":"A randomized controlled trial comparing the efficacy of Cyp3a5 genotype-based with body-weight-based tacrolimus dosing after living donor kidney transplantation","volume":"16","author":"Shuker","year":"2016","journal-title":"Am J Transpl"},{"key":"R11-20250108","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1111\/ajt.12955","article-title":"Novel once-daily extended-release tacrolimus (LCPT) versus twice-daily tacrolimus in de novo kidney transplants: one-year results of phase III, double-blind, randomized trial","volume":"14","author":"Budde","year":"2014","journal-title":"Am J Transpl"},{"key":"R12-20250108","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.kint.2023.06.021","article-title":"A prospective controlled, randomized clinical trial of kidney transplant recipients developed personalized tacrolimus dosing using model-based Bayesian Prediction","volume":"104","author":"Lloberas","year":"2023","journal-title":"Kidney Int"},{"key":"R13-20250108","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/tri.12699","article-title":"Lower tacrolimus trough levels are associated with subsequently higher acute rejection risk during the first 12 months after kidney transplantation","volume":"29","author":"Gaynor","year":"2016","journal-title":"Transpl Int"},{"key":"R14-20250108","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1111\/tri.12155","article-title":"Tacrolimus trough levels after month 3 as a predictor of acute rejection following kidney transplantation: a lesson learned from DeKAF Genomics","volume":"26","author":"Israni","year":"2013","journal-title":"Transpl Int."},{"key":"R15-20250108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1097\/00007890-199610150-00009","article-title":"Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation","volume":"62","author":"Kershner","year":"1996","journal-title":"Transplantation"},{"key":"R16-20250108","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/TP.0000000000002913","article-title":"Tacrolimus intrapatient variability, time in therapeutic range, and risk of de novo donor-specific antibodies","volume":"104","author":"Davis","year":"2020","journal-title":"Transplantation"},{"key":"R17-20250108","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.14504","article-title":"Lower tacrolimus exposure and time in therapeutic range increase the risk of de novo donor-specific antibodies in the first year of kidney transplantation","volume":"18","author":"Davis","year":"2018","journal-title":"Am J Transpl"},{"key":"R18-20250108","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1681\/ASN.2017030287","article-title":"Class II Eplet mismatch modulates tacrolimus trough levels required to prevent donor-specific antibody development","volume":"28","author":"Wiebe","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"R19-20250108","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00228-017-2234-2","article-title":"The incidence of post-transplant cancer among kidney transplant recipients is associated with the level of tacrolimus exposure during the first year after transplantation","volume":"73","author":"Lichtenberg","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"R20-20250108","doi-asserted-by":"crossref","first-page":"587","DOI":"10.3390\/jcm8050587","article-title":"Fast Tac metabolizers at risk \u2212 it is time for a C\/D ratio calculation","volume":"8","author":"Sch\u00fctte-N\u00fctgen","year":"2019","journal-title":"J Clin Med"},{"key":"R21-20250108","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1097\/TP.0000000000002920","article-title":"The TOMATO Study (tacrolimus metabolization in kidney transplantation): impact of the concentration-dose ratio on death-censored graft survival","volume":"104","author":"Jouve","year":"2020","journal-title":"Transplantation"},{"key":"R22-20250108","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3389\/fphar.2020.01142","article-title":"The clinical impact of the C0\/D ratio and the CYP3A5 genotype on outcome in tacrolimus treated kidney transplant recipients","volume":"11","author":"van Gelder","year":"2020","journal-title":"Front Pharmacol"},{"key":"R23-20250108","first-page":"248","article-title":"Improving long-term outcomes of kidney transplantation: the pressure is on","volume":"72","author":"Hesselink","year":"2014","journal-title":"Neth J Med"},{"key":"R24-20250108","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/bcp.13838","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients","volume":"85","author":"Andrews","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R25-20250108","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.nefro.2022.12.005","article-title":"Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio","volume":"44","author":"Vidal-Alabr\u00f3","year":"2024","journal-title":"Nefrologia"},{"key":"R26-20250108","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","article-title":"Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference","volume":"31","author":"Wallemacq","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R27-20250108","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nrneph.2014.172","article-title":"Pharmacogenetics and immunosuppressive drugs in solid organ transplantation","volume":"10","author":"van Gelder","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"R28-20250108","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"R29-20250108","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","article-title":"Importance of hematocrit for a tacrolimus target concentration strategy","volume":"70","author":"St\u00f8rset","year":"2014","journal-title":"Eur J Clin Pharmacol"},{"key":"R30-20250108","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s40262-016-0491-3","article-title":"A new CYP3A5*3 and CYP3A4*22 cluster influencing tacrolimus target concentrations: a population approach","volume":"56","author":"Andreu","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"R31-20250108","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0272-6386(00)70013-8","article-title":"Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients","volume":"35","author":"Wong","year":"2000","journal-title":"Am J Kidney Dis"},{"key":"R32-20250108","doi-asserted-by":"crossref","first-page":"683","DOI":"10.2165\/11535950-000000000-00000","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in renal transplant recipients on a new once-daily formulation","volume":"49","author":"Benkali","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R33-20250108","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2125.2010.03837.x","article-title":"Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations\u2014twice daily Prograf and once daily Advagraf","volume":"71","author":"Woillard","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"R34-20250108","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/FTD.0b013e31827efe37","article-title":"A limited sampling strategy to estimate the area under the concentration-time curve of tacrolimus modified-release once-daily preparation in renal transplant recipients","volume":"35","author":"Niioka","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R35-20250108","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00228-019-02814-x","article-title":"A limited sampling strategy to estimate exposure of once-daily modified release tacrolimus in renal transplant recipients using linear regression analysis and comparison with Bayesian population pharmacokinetics in different cohorts","volume":"76","author":"Stifft","year":"2020","journal-title":"Eur J Clin Pharmacol"},{"key":"R36-20250108","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","article-title":"Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus","volume":"74","author":"Hesselink","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"R37-20250108","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/FPC.0000000000000296","article-title":"The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation","volume":"27","author":"Lloberas","year":"2017","journal-title":"Pharmacogenet Genomics"},{"key":"R38-20250108","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1373\/clinchem.2011.165613","article-title":"A new functional CYP3A4 intron 6 polymorphism significantly affects tacrolimus pharmacokinetics in kidney transplant recipients","volume":"57","author":"Elens","year":"2011","journal-title":"Clin Chem"},{"key":"R39-20250108","doi-asserted-by":"crossref","first-page":"728","DOI":"10.5414\/CP202152","article-title":"The genetic polymorphisms of POR*28 and CYP3A5*3 significantly influence the pharmacokinetics of tacrolimus in Chinese renal transplant recipients","volume":"53","author":"Zhang","year":"2015","journal-title":"Int J Clin Pharmacol Ther"},{"key":"R40-20250108","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3389\/fphar.2017.00358","article-title":"Tacrolimus updated guidelines through popPK modeling: how to benefit more from CYP3A pre-emptive genotyping prior to kidney transplantation","volume":"8","author":"Woillard","year":"2017","journal-title":"Front Pharmacol"},{"key":"R41-20250108","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejps.2013.10.008","article-title":"Total plasma protein effect on tacrolimus elimination in kidney transplant patients\u2014population pharmacokinetic approach","volume":"52","author":"Golubovi\u0107","year":"2014","journal-title":"Eur J Pharm Sci"},{"key":"R42-20250108","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1038\/clpt.2011.34","article-title":"Pharmacogenetics: from bench to byte--an update of guidelines","volume":"89","author":"Swen","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"R43-20250108","doi-asserted-by":"crossref","first-page":"912618","DOI":"10.3389\/fphar.2022.912618","article-title":"Why we need to take a closer look at genetic contributions to CYP3A activity","volume":"13","author":"Zhai","year":"2022","journal-title":"Front Pharmacol"},{"key":"R44-20250108","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s40262-013-0120-3","article-title":"The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation","volume":"53","author":"Hesselink","year":"2014","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"R45-20250108","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1097\/FTD.0000000000000255","article-title":"Pharmacogenetic biomarkers predictive of the pharmacokinetics and pharmacodynamics of immunosuppressive drugs","volume":"38","author":"Picard","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R46-20250108","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/clpt.2010.42","article-title":"Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?","volume":"87","author":"van Gelder","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"R47-20250108","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1186\/1753-6561-8-S1-S102","article-title":"Estimating proportions of explained variance: a comparison of whole genome subsets","volume":"8","author":"Aslibekyan","year":"2014","journal-title":"BMC Proc."},{"key":"R48-20250108","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13059-021-02403-1","article-title":"GxEsum: a novel approach to estimate the phenotypic variance explained by genome-wide GxE interaction based on GWAS summary statistics for biobank-scale data","volume":"22","author":"Shin","year":"2021","journal-title":"Genome Biol."},{"key":"R49-20250108","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3390\/pharmaceutics14020261","article-title":"Association of P450 oxidoreductase gene polymorphism with tacrolimus pharmacokinetics in renal transplant recipients: a systematic review and meta-analysis","volume":"14","author":"Lee","year":"2022","journal-title":"Pharmaceutics"},{"key":"R50-20250108","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s40262-018-0717-7","article-title":"Pharmacogenetics of membrane transporters of tacrolimus in solid organ transplantation","volume":"58","author":"Tron","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"R51-20250108","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R52-20250108","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2165\/11317550-000000000-00000","article-title":"Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II","volume":"49","author":"Staatz","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"R53-20250108","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2174\/138945011795378487","article-title":"Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCC2 and their impact on drug disposition","volume":"12","author":"Haufroid","year":"2011","journal-title":"Curr Drug Targets"},{"key":"R54-20250108","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.7754\/Clin.Lab.2016.160221","article-title":"The effect of ABCB1 polymorphisms on serial tacrolimus concentrations in stable Austrian long-term kidney transplant recipients","volume":"62","author":"Riegersperger","year":"2016","journal-title":"Clin Lab"},{"key":"R55-20250108","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5414\/CNP88FX25","article-title":"The role of single nucleotide polymorphisms of CYP3A and ABCB1 on tacrolimus predose concentration in kidney transplant recipients","volume":"88","author":"Mlin\u0161ek","year":"2017","journal-title":"Clin Nephrol"},{"key":"R56-20250108","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7754\/Clin.Lab.2019.190343","article-title":"Effect of CYP3A5 and ABCB1 gene polymorphisms on tacrolimus blood concentration in renal transplant recipients","volume":"65","author":"Yildirim","year":"2019","journal-title":"Clin Lab"},{"key":"R57-20250108","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/FTD.0b013e31828c1581","article-title":"Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus","volume":"35","author":"Vafadari","year":"2013","journal-title":"Ther Drug Monit"},{"key":"R58-20250108","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2217\/pgs.10.43","article-title":"CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation","volume":"11","author":"Capron","year":"2010","journal-title":"Pharmacogenomics"},{"key":"R59-20250108","doi-asserted-by":"crossref","first-page":"e0230195","DOI":"10.1371\/journal.pone.0230195","article-title":"Pharmacogenetic\u2014whole blood and intracellular pharmacokinetic\u2014pharmacodynamic (PG-PK2-PD) relationship of tacrolimus in liver transplant recipients","volume":"15","author":"Tron","year":"2020","journal-title":"PLoS One"},{"key":"R60-20250108","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.3390\/pharmaceutics15051481","article-title":"The effect of intracellular tacrolimus exposure on calcineurin inhibition in immediate- and extended-release tacrolimus formulations","volume":"15","author":"Fontova","year":"2023","journal-title":"Pharmaceutics"},{"key":"R61-20250108","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1124\/dmd.30.8.883","article-title":"Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7","volume":"30","author":"Williams","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"R62-20250108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"key":"R63-20250108","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00008571-200112000-00005","article-title":"The genetic determinants of the CYP3A5 polymorphism","volume":"11","author":"Hustert","year":"2001","journal-title":"Pharmacogenetics"},{"key":"R64-20250108","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/clpt.2013.68","article-title":"CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients","volume":"94","author":"Santoro","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"R65-20250108","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/clinchem\/48.10.1668","article-title":"CYP3A5 variant allele frequencies in Dutch Caucasians","volume":"48","author":"van Schaik","year":"2002","journal-title":"Clin Chem"},{"key":"R66-20250108","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1002\/cpt.2563","article-title":"PharmVar GeneFocus: CYP3A5","volume":"112","author":"Rodriguez-Antona","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"R67-20250108","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00008571-200403000-00002","article-title":"The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients","volume":"14","author":"Haufroid","year":"2004","journal-title":"Pharmacogenetics"},{"key":"R68-20250108","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1097\/01.TP.0000137789.58694.B4","article-title":"Influence of CYP3A5 and MDR1 (ABCB1) polymorphisms on the pharmacokinetics of tacrolimus in renal transplant recipients","volume":"78","author":"Tsuchiya","year":"2004","journal-title":"Transplantation"},{"key":"R69-20250108","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/FPC.0b013e32834a48ca","article-title":"Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers","volume":"21","author":"Tang","year":"2011","journal-title":"Pharmacogenet Genomics"},{"key":"R70-20250108","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1097\/FPC.0b013e3283557c74","article-title":"The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis","volume":"22","author":"Terrazzino","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"R71-20250108","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/01.TP.0000151766.73249.12","article-title":"Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians","volume":"79","author":"Macphee","year":"2005","journal-title":"Transplantation"},{"key":"R72-20250108","doi-asserted-by":"crossref","first-page":"e0127995","DOI":"10.1371\/journal.pone.0127995","article-title":"Effects of the CYP3A4*1B genetic polymorphism on the pharmacokinetics of tacrolimus in adult renal transplant recipients: a meta-analysis","volume":"10","author":"Shi","year":"2015","journal-title":"PLoS One"},{"key":"R73-20250108","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/FPC.0b013e32835fcbb6","article-title":"Effects of CYP3A4 and CYP3A5 polymorphisms on tacrolimus pharmacokinetics in Chinese adult renal transplant recipients: a population pharmacokinetic analysis","volume":"23","author":"Zuo","year":"2013","journal-title":"Pharmacogenet Genomics"},{"key":"R74-20250108","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/humu.9210","article-title":"Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population","volume":"23","author":"Fukushima-Uesaka","year":"2004","journal-title":"Hum Mutat"},{"key":"R75-20250108","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/tpj.2010.28","article-title":"Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs","volume":"11","author":"Wang","year":"2011","journal-title":"Pharmacogenomics J"},{"key":"R76-20250108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1097\/FPC.0b013e32834c6edb","article-title":"Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study","volume":"21","author":"Elens","year":"2011","journal-title":"Pharmacogenet Genomics."},{"key":"R77-20250108","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/tpj.2014.67","article-title":"High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme","volume":"15","author":"Apell\u00e1niz-Ruiz","year":"2015","journal-title":"Pharmacogenomics J"},{"key":"R78-20250108","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/pgs-2017-0301","article-title":"Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype","volume":"19","author":"Lloberas","year":"2018","journal-title":"Pharmacogenomics"},{"key":"R79-20250108","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2217\/pgs-2017-0131","article-title":"Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?","volume":"18","author":"Elens","year":"2017","journal-title":"Pharmacogenomics"},{"key":"R80-20250108","doi-asserted-by":"crossref","first-page":"869554","DOI":"10.3389\/fimmu.2022.869554","article-title":"Tacrolimus CYP3A single-nucleotide polymorphisms and preformed T- and B-cell alloimmune memory improve current pretransplant rejection-risk stratification in kidney transplantation","volume":"13","author":"Crespo","year":"2022","journal-title":"Front Immunol"},{"key":"R81-20250108","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.3390\/ijms21072287","article-title":"Influence of POR*28 polymorphisms on CYP3A5*3-associated variations in tacrolimus blood levels at an early stage after liver transplantation","volume":"21","author":"Nakamura","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R82-20250108","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.2217\/pgs.11.77","article-title":"The P450 oxidoreductase *28 SNP is associated with low initial tacrolimus exposure and increased dose requirements in CYP3A5-expressing renal recipients","volume":"12","author":"De Jonge","year":"2011","journal-title":"Pharmacogenomics"},{"key":"R83-20250108","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1002\/cpt.593","article-title":"Scalpels not hammers: the way forward for precision drug prescription","volume":"101","author":"Neely","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"R84-20250108","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s40262-016-0396-1","article-title":"Population pharmacokinetic modelling and Bayesian estimation of tacrolimus exposure: is this clinically useful for dosage prediction yet?","volume":"55","author":"Brooks","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"R85-20250108","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/jcph.1325","article-title":"Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities?","volume":"59","author":"Campagne","year":"2019","journal-title":"J Clin Pharmacol."},{"key":"R86-20250108","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","article-title":"Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review","volume":"59","author":"Kirubakaran","year":"2020","journal-title":"Clin Pharmacokinet"},{"key":"R87-20250108","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s40262-024-01414-y","article-title":"Model-informed precision dosing of tacrolimus: a systematic review of population pharmacokinetic models and a benchmark study of software tools","volume":"63","author":"Hoffert","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"R88-20250108","doi-asserted-by":"crossref","first-page":"5317","DOI":"10.1007\/s12325-021-01905-5","article-title":"Therapeutic drug monitoring strategies for Envarsus in de novo kidney transplant patients using population modelling and simulations","volume":"38","author":"Henin","year":"2021","journal-title":"Adv Ther"},{"key":"R89-20250108","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.3390\/pharmaceutics15122699","article-title":"CYP3A5*3 and CYP3A4*22 cluster polymorphism effects on LCP-Tac tacrolimus exposure: population pharmacokinetic approach","volume":"15","author":"Mohammed Ali","year":"2023","journal-title":"Pharmaceutics"},{"key":"R90-20250108","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1053\/j.ajkd.2017.07.018","article-title":"Results of ASERTAA, a randomized prospective crossover pharmacogenetic study of immediate-release versus extended-release tacrolimus in African American kidney transplant recipients","volume":"71","author":"Trofe-Clark","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"R91-20250108","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/ajt.13935","article-title":"A steady-state head-to-head pharmacokinetic comparison of all FK-506 (tacrolimus) formulations (ASTCOFF): an open-label, prospective, randomized, Two-Arm, three-period crossover Study","volume":"17","author":"Tremblay","year":"2017","journal-title":"Am J Transpl"},{"key":"R92-20250108","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1002\/cpt.2220","article-title":"Sustained inhibition of calcineurin activity with a melt-dose once-daily tacrolimus formulation in renal transplant recipients","volume":"110","author":"Fontova","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R93-20250108","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1124\/dmd.118.081935","article-title":"Relationship between in vivo CYP3A4 activity, CYP3A5 genotype, and systemic tacrolimus metabolite\/parent drug ratio in renal transplant recipients and healthy volunteers","volume":"46","author":"Vanhove","year":"2018","journal-title":"Drug Metab Dispos"},{"key":"R94-20250108","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/0091270011423661","article-title":"A simultaneous D-optimal designed Study for population pharmacokinetic analyses of mycophenolic acid and tacrolimus early after renal transplantation","volume":"52","author":"Musuamba","year":"2012","journal-title":"J Clin Pharmacol"},{"key":"R95-20250108","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/FTD.0b013e3181bf8623","article-title":"Time of drug administration, CYP3A5 and ABCB1 genotypes, and analytical method influence tacrolimus pharmacokinetics: a population pharmacokinetic Study","volume":"31","author":"Musuamba","year":"2009","journal-title":"Ther Drug Monit"},{"key":"R96-20250108","doi-asserted-by":"crossref","first-page":"1456565","DOI":"10.3389\/fphar.2024.1456565","article-title":"Guiding the starting dose of the once-daily formulation of tacrolimus in \u201cde novo\u201d adult renal transplant patients: a population approach","volume":"15","author":"Fern\u00e1ndez-Alarc\u00f3n","year":"2024","journal-title":"Front Pharmacol"},{"key":"R97-20250108","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/jcpt.12599","article-title":"Population pharmacokinetics and Bayesian estimation of tacrolimus exposure in Chinese liver transplant patients","volume":"42","author":"Chen","year":"2017","journal-title":"J Clin Pharm Ther."},{"key":"R98-20250108","first-page":"547","article-title":"Correction to: once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations","volume":"11","author":"Griny\u00f3","year":"2015","journal-title":"Expert Rev Clin Immunol."},{"key":"R99-20250108","first-page":"1552","article-title":"Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism","volume":"283","author":"Paine","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"R100-20250108","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.clinthera.2014.02.021","article-title":"Assessment of tacrolimus absorption from the human intestinal tract: open-label, randomized, 4-way crossover Study","volume":"36","author":"Tsunashima","year":"2014","journal-title":"Clin Ther"},{"key":"R101-20250108","first-page":"414","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"key":"R102-20250108","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1023\/A:1026183200740","article-title":"P-glycoprotein increases from proximal to distal regions of human small intestine","volume":"20","author":"Mouly","year":"2003","journal-title":"Pharm Res"},{"key":"R103-20250108","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1021\/mp100015x","article-title":"Effect of variations in the amounts of P-glycoprotein (ABCB1), BCRP (ABCG2) and CYP3A4 along the human small intestine on PBPK models for predicting intestinal first pass","volume":"7","author":"Bruy\u00e8re","year":"2010","journal-title":"Mol Pharm"},{"key":"R104-20250108","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1097\/TP.0000000000000708","article-title":"Improved tacrolimus target concentration achievement using computerized dosing in renal transplant recipients--A prospective, randomized Study","volume":"99","author":"St\u00f8rset","year":"2015","journal-title":"Transplantation"},{"key":"R105-20250108","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s40262-017-0567-8","article-title":"A population pharmacokinetic model to predict the individual starting dose of tacrolimus following pediatric renal transplantation","volume":"57","author":"Andrews","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"R106-20250108","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/tri.12194","article-title":"Inclusion of CYP3A5 genotyping in a nonparametric population model improves dosing of tacrolimus early after transplantation","volume":"26","author":"\u00c5sberg","year":"2013","journal-title":"Transpl Int"},{"key":"R107-20250108","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1742-7843.2008.00327.x","article-title":"Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients","volume":"103","author":"Quteineh","year":"2008","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"R108-20250108","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/FTD.0b013e3182731809","article-title":"Impact of tacrolimus intraindividual variability and CYP3A5 genetic polymorphism on acute rejection in kidney transplantation","volume":"34","author":"Ro","year":"2012","journal-title":"Ther Drug Monit"},{"key":"R109-20250108","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/cpt.2163","article-title":"Avoiding tacrolimus underexposure and overexposure with a dosing algorithm for renal transplant recipients: a single arm prospective intervention trial","volume":"110","author":"Francke","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"R110-20250108","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.kint.2023.06.036","article-title":"A first small step toward personalized immunosuppression","volume":"104","author":"Budde","year":"2023","journal-title":"Kidney Int"},{"key":"R111-20250108","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1007\/s40262-020-00955-2","article-title":"Clinical impact of the adaptation of initial tacrolimus dosing to the CYP3A5 genotype after kidney transplantation: systematic review and meta-analysis of randomized controlled trials","volume":"60","author":"Yang","year":"2021","journal-title":"Clin Pharmacokinet"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001289","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T15:02:17Z","timestamp":1736348537000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001289"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,10]]},"references-count":111,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001289","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,10]]},"assertion":[{"value":"2024-09-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-22","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}